DCAT Sharp Sourcing is our completely virtual education series connecting DCAT members to industry thought leaders from around the world using state-of-the-art livestream technology. As a benefit of your DCAT membership, you have exclusive access to high-level education programs at a deeply discounted price. 

And now, everyone can attend. Developed by volunteers on DCAT's Supply Management Committee, DCAT Sharp Sourcing offers several webinars throughout the year at a fraction of the cost typically found for such executive-level programs. The webinars provide our members access to high-profile speakers on timely topics of greatest importance to the pharma customer-supplier relationship.

Save the Date: Upcoming Sharp Sourcing Webinar:
Re-Inventing Global Pharma Supply Chains

Tuesday November 10, 2020 • 11:00 AM to 12:30 PM ET 

The novel coronavirus (COVID-19) pandemic has made the pharmaceutical industry further re-examine its manufacturing networks and supply chains as a means to mitigate potential supply disruptions. Going forward, what do pharmaceutical companies, CDMOs, CMOs, and suppliers have to consider to assure supply of raw materials, intermediates, active pharmaceutical ingredients (APIs), and other materials used in drug manufacturing? Will it take a re-invention of sourcing and supply practices?

This 90-minute interactive webinar brings together a panel of industry experts to offer valuable and practical insights into what companies need to consider and the options available to them for further fortifying their manufacturing and supply chains. This webinar will address:

• The New Normal in Manufacturing and Supply Networks: An inside-the-trenches view from a pharmaceutical executive provides a candid assessment of the extent, and how, pharma companies and their suppliers can reduce vulnerabilities in their manufacturing and supply networks. 
• Repatriation to Increase Domestic Drug Manufacturing: Both the US and the EU have policy proposals on the table to either require or incentivize the onshoring of drug manufacturing. Where do those proposals stand, how feasible are these proposals coming to fruition, and what is the impact for the pharma industry?
• Sourcing from China: China is an important source of chemicals, raw materials, intermediates, and APIs, but do supply chains have to be re-evaluated to mitigate supply risks, and if so, what sourcing and supply practices can reduce vulnerabilities? How are other issues, such as evolving trade policies, further affecting sourcing strategies from China?